IgG accumulates in inhibitory hippocampal neurons of experimental antiphospholipid syndrome

Journal of Autoimmunity

Volumn 55, Issue 1, 2014, Pages 86-93

  Katzav, Aviva ^a   Menachem, Assaf ^a   Maggio, Nicola ^a,b   Pollak, Lea ^a   Pick, Chaim G ^a   Chapman, Joab ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

Antiphospholipid antibodies; Blood brain barrier; Experimental antiphospholipid syndrome; Hippocampus; Hyperactivity; Inhibitory interneurons

Indexed keywords

CARBACHOL; EVANS BLUE; GLUTAMATE DECARBOXYLASE 67; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; PHOSPHOLIPID ANTIBODY; BETA2 GLYCOPROTEIN 1; GLUTAMATE DECARBOXYLASE; GLUTAMATE DECARBOXYLASE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; ELECTROPHYSIOLOGICAL PROCEDURES; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIPPOCAMPUS; IMMUNIZATION; IMMUNOFLUORESCENCE; IN VIVO STUDY; INTERNEURON; MOUSE; NERVE CELL; NONHUMAN; OSCILLATION; PRIORITY JOURNAL; REARING; STAIRCASE TEST; ANIMAL; BAGG ALBINO MOUSE; CHEMICALLY INDUCED; DISEASE MODEL; IMMUNOLOGY; PATHOLOGY; PATHOPHYSIOLOGY;

ANIMALS; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; DISEASE MODELS, ANIMAL; FEMALE; GLUTAMATE DECARBOXYLASE; HIPPOCAMPUS; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; NEURONS;

EID: 84922395739     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2014.07.006     Document Type: Article

References (43)

1. Rand J.H. Molecular pathogenesis of the antiphospholipid syndrome. Circ Res 2002, 90:29-37.
2. Ferreira S., D'Cruz D.P., Hughes G.R. Multiple sclerosis, neuropsychiatric lupus and antiphospholipid syndrome: where do we stand?. Rheumatology (Oxford) 2005, 44:434-442.
3. Durrani O.M., Gordon C., Murray P.I. Primary anti-phospholipid antibody syndrome (APS): current concepts. Surv Ophthalmol 2002, 47:215-238.
4. Roubey R.A., Hoffman M. From antiphospholipid syndrome to antibody-mediated thrombosis. Lancet 1997, 350:1491-1493.
5. Chapman J., Cohen-Armon M., Shoenfeld Y., Korczyn A.D. Antiphospholipid antibodies permeabilize and depolarize brain synaptoneurosomes. Lupus 1999, 8:127-133.
6. Katzav A., Litvinjuk Y., Pick C.G., Blank M., Shoenfeld Y., Sirota P., et al. Genetic and immunological factors interact in a mouse model of CNS antiphospholipid syndrome. Behav Brain Res 2006, 169:289-293.
7. Mosek A., Yust I., Treves T.A., Vardinon N., Korczyn A.D., Chapman J. Dementia and antiphospholipid antibodies. Dement Geriatr Cogn Disord 2000, 11:36-38.
8. Shoenfeld Y., Nahum A., Korczyn A.D., Dano M., Rabinowitz R., Beilin O., et al. Neuronal-binding antibodies from patients with antiphospholipid syndrome induce cognitive deficits following intrathecal passive transfer. Lupus 2003, 12:436-442.
9. Menachem A., Chapman J., Katzav A. Hyperactivity induced by antiphospholipid syndrome serum. Ann N Y Acad Sci 2009, 1173:422-426.
10. Rabchevsky A.G., Degos J.D., Dreyfus P.A. Peripheral injections of Freund's adjuvant in mice provoke leakage of serum proteins through the blood-brain barrier without inducing reactive gliosis. Brain Res 1999, 832:84-96.
11. Tanne D., Katzav A., Beilin O., Grigoriadis N.C., Blank M., Pick C.G., et al. Interaction of inflammation, thrombosis, aspirin and enoxaparin in CNS experimental antiphospholipid syndrome. Neurobiol Dis 2008, 30:56-64.
12. Gharavi A.E., Sammaritano L.R., Wen J., Elkon K.B. Induction of antiphospholipid autoantibodies by immunization with beta 2 glycoprotein I (apolipoprotein H). JClin Invest 1992, 90:1105-1109.
13. Katzav A., Pick C.G., Korczyn A.D., Oest E., Blank M., Shoenfeld Y., et al. Hyperactivity in a mouse model of the antiphospholipid syndrome. Lupus 2001, 10:496-499.
14. Shrot S., Katzav A., Korczyn A.D., Litvinju Y., Hershenson R., Pick C.G., et al. Behavioral and cognitive deficits occur only after prolonged exposure of mice to antiphospholipid antibodies. Lupus 2002, 11:736-743.
15. Bakimer R., Fishman P., Blank M., Sredni B., Djaldetti M., Shoenfeld Y. Induction of primary antiphospholipid syndrome in mice by immunization with a human monoclonal anticardiolipin antibody (H-3). JClin Invest 1992, 89:1558-1563.
16. Maggio N., Segal M. Unique regulation of long term potentiation in the rat ventral hippocampus. Hippocampus 2007, 17:10-25.
17. Wojtowicz A.M., van den Boom L., Chakrabarty A., Maggio N., Haq R.U., Behrens C.J., et al. Monoamines block kainate- and carbachol-induced gamma-oscillations but augment stimulus-induced gamma-oscillations in rat hippocampus invitro. Hippocampus 2009, 19:273-288.
18. Chapman J., Abu-Katash M., Inzelberg R., Yust I., Neufeld M.Y., Vardinon N., et al. Prevalence and clinical features of dementia associated with the antiphospholipid syndrome and circulating anticoagulants. JNeurol Sci 2002, 203-204:81-84.
19. Correale J., Villa A. Cellular elements of the blood-brain barrier. Neurochem Res 2009, 34:2067-2077.
20. Namer I.J., Steibel J., Poulet P., Mauss Y., Mohr M., Chambron J. The role of Mycobacterium tuberculosis in experimental allergic encephalomyelitis. Eur Neurol 1994, 34:224-227.
21. Walls A.F., Suckling A.J., Rumsby M.G. Autoantibody responses in the cerebrospinal fluid of guinea pigs with chronic relapsing experimental allergic encephalomyelitis. Acta Neurol Scand 1988, 78:422-428.
22. Nunzi M.G., Gorio A., Milan F., Freund T.F., Somogyi P., Smith A.D. Cholecystokinin-immunoreactive cells form symmetrical synaptic contacts with pyramidal and nonpyramidal neurons in the hippocampus. JComp Neurol 1985, 237:485-505.
23. Freund T.F., Buzsaki G. Interneurons of the hippocampus. Hippocampus 1996, 6:347-470.
24. Weizman R., Paz L., Peter Y., Toren P., Pick C.G. Behavioral effects of agents active at the gamma-aminobutyric acid receptor complex in the staircase paradigm. Brain Res 2001, 901:137-142.
25. Shoenfeld Y., Lev S., Blatt I., Blank M., Font J., von Landenberg P., et al. Features associated with epilepsy in the antiphospholipid syndrome. JRheumatol 2004, 31:1344-1348.
26. Frauenknecht K., Katzav A., Grimm C., Chapman J., Sommer C.J. Neurological impairment in experimental antiphospholipid syndrome is associated with increased ligand binding to hippocampal and cortical serotonergic 5-HT1A receptors. Immunobiology 2013, 218:517-526.
27. Bartos M., Vida I., Jonas P. Synaptic mechanisms of synchronized gamma oscillations in inhibitory interneuron networks. Nat Rev Neurosci 2007, 8:45-56.
28. Goldstein J.L., Anderson R.G., Brown M.S. Coated pits, coated vesicles, and receptor-mediated endocytosis. Nature 1979, 279:679-685.
29. Okada C.Y., Rechsteiner M. Introduction of macromolecules into cultured mammalian cells by osmotic lysis of pinocytic vesicles. Cell 1982, 29:33-41.
30. Zack D.J., Stempniak M., Wong A.L., Taylor C., Weisbart R.H. Mechanisms of cellular penetration and nuclear localization of an anti-double strand DNA autoantibody. JImmunol 1996, 157:2082-2088.
31. Tezel G., Wax M.B. The mechanisms of hsp27 antibody-mediated apoptosis in retinal neuronal cells. JNeurosci 2000, 20:3552-3562.
32. Tse E., Rabbitts T.H. Intracellular antibody-caspase-mediated cell killing: an approach for application in cancer therapy. Proc Natl Acad Sci U S A 2000, 97:12266-12271.
33. Danon Y.L., Garty B.Z. Autoantibodies to neuroblastoma cell surface antigens in neuropsychiatric lupus. Neuropediatrics 1986, 17:23-27.
34. Bluestein H.G., Williams G.W., Steinberg A.D. Cerebrospinal fluid antibodies to neuronal cells: association with neuropsychiatric manifestations of systemic lupus erythematosus. Am J Med 1981, 70:240-246.
35. Omdal R., Brokstad K., Waterloo K., Koldingsnes W., Jonsson R., Mellgren S.I. Neuropsychiatric disturbances in SLE are associated with antibodies against NMDA receptors. Eur J Neurol 2005, 12:392-398.
36. Ball-Rosen C., Primak-Rubinovicz H., Korczyn A.D., Wang N., Farchi A., Shavit S., et al. Identification of histidine-rich glycoprotein, a potential autoantigen, in human and rat brain preparations. Ann N Y Acad Sci 2007, 1109:473-483.
37. Dalmau J., Rosenfeld M.R. Paraneoplastic syndromes of the CNS. Lancet Neurol 2008, 7:327-340.
38. Irani S.R., Vincent A. Autoimmune encephalitis - new awareness, challenging questions. Discov Med 2011, 11:449-458.
39. Irani S.R., Bera K., Waters P., Zuliani L., Maxwell S., Zandi M.S., et al. N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain 2010, 133:1655-1667.
40. Jarius S., Hoffmann L.A., Stich O., Clover L., Rauer S., Vincent A., et al. Relative frequency of VGKC and 'classical' paraneoplastic antibodies in patients with limbic encephalitis. JNeurol 2008, 255:1100-1101.
41. Malter M.P., Helmstaedter C., Urbach H., Vincent A., Bien C.G. Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis. Ann Neurol 2010, 67:470-478.
42. Pellkofer H.L., Kuempfel T., Jacobson L., Vincent A., Derfuss T. Non-paraneoplastic limbic encephalitis associated with NMDAR and VGKC antibodies. JNeurol Neurosurg Psychiatr 2010, 81:1407-1408.
43. Chapman J., Alroy G., Weiss Z., Faigon M., Feldon J., Michaelson D.M. Anti-neuronal antibodies similar to those found in Alzheimer's disease induce memory dysfunction in rats. Neuroscience 1991, 40:297-305.